S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Gilead Sciences (GILD) Stock Price, News & Analysis

-0.38 (-0.56%)
(As of 04/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
5.28 million shs
Average Volume
7.32 million shs
Market Capitalization
$83.33 billion
P/E Ratio
Dividend Yield
Price Target

Gilead Sciences MarketRank™ Stock Analysis

Analyst Rating
2.27 Rating Score
27.5% Upside
$85.36 Price Target
Short Interest
1.81% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.92mentions of Gilead Sciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$292,280 Sold Last Quarter
Proj. Earnings Growth
From $7.06 to $7.32 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

5.00 out of 5 stars

Medical Sector

2nd out of 913 stocks

Biological Products, Except Diagnostic Industry

1st out of 134 stocks

GILD stock logo

About Gilead Sciences Stock (NASDAQ:GILD)

Gilead Sciences, Inc. is a leading biopharmaceutical company in Foster City, California. Founded in 1987, the company's mission is to develop innovative medicines that address unmet medical needs and improve the lives of people around the world. Gilead focuses on discovering, developing, and commercializing therapies in HIV/AIDS, liver diseases, oncology, inflammatory and respiratory diseases, and cardiovascular conditions. 

Gilead's portfolio includes a wide range of products and therapies, with its most notable product being Truvada, a leading medication for HIV prevention. The company also offers other HIV treatments, such as Biktarvy and Descovy. In addition to its HIV franchise, Gilead has significantly advanced in treating chronic hepatitis B and C with drugs like Veklury and Epclusa. Furthermore, the company has expanded into oncology with therapies such as Trodelvy and Yescarta.

Gilead Sciences is led by experienced executives who bring industry knowledge and expertise. The company's Chief Executive Officer, Daniel O'Day, joined Gilead in 2019 and has a proven track record in the pharmaceutical industry. O'Day previously served as the CEO of Roche Pharmaceuticals, where he successfully led the company through significant growth.

Gilead Sciences has consistently delivered a solid financial performance in recent years. The company has reported strong revenue and net income numbers yearly. This growth was primarily driven by solid sales of Gilead's HIV and liver disease therapies. The company averages a profit margin between 25% - 30%. Gilead has maintained a healthy balance sheet with manageable levels of debt. Gilead's strong financial position allows it to invest in research and development initiatives and pursue strategic acquisitions to drive future growth.

Investor sentiment towards Gilead has improved in recent years due to the company's strong financial performance and promising pipeline of innovative therapies. The successful launch of new products, such as Trodelvy and Biktarvy, has further bolstered investor confidence in Gilead's growth prospects.

Gilead Sciences operates in the highly competitive biopharmaceutical industry, characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The industry is subject to evolving market dynamics, including changing reimbursement policies, patent expirations, and intense competition from established and emerging biotech firms.

Gilead's expansion into oncology has been promising, with the introduction of therapies targeting specific types of cancer. However, the oncology market is highly competitive, with several significant players and emerging biotechs vying for market share. Gilead's success in this area will depend on its ability to differentiate its products, demonstrate clinical efficacy, and navigate the evolving treatment landscape.

Gilead Sciences has identified several growth opportunities that can contribute to its future success. One key focus is expanding its product portfolio through internal research and development efforts and strategic acquisitions and partnerships. By investing in innovative therapies, Gilead aims to address unmet medical needs and strengthen its competitive position.

The company's pipeline includes potential breakthrough treatments for various diseases, including novel antiviral agents, immunology candidates, and cell therapies. Gilead also explores combination therapies to enhance treatment outcomes and extend its market reach. These advancements provide opportunities for revenue growth and market expansion.

Gilead Sciences faces risks and challenges that could impact its performance and prospects. One of the primary challenges for Gilead is the potential for generic competition. As patents on some of its key products expire, there is a risk of generic manufacturers entering the market with lower-priced alternatives. This can lead to pricing pressures and a decline in market share for Gilead's established therapies. The company must continue to innovate and develop new drugs to mitigate the impact of generic competition.

Another challenge is the evolving regulatory environment. Changes in healthcare policies, pricing regulations, and reimbursement systems can significantly impact the profitability of pharmaceutical companies. Gilead operates in multiple regions and must navigate various regulatory frameworks, which can introduce uncertainties and challenges to its business operations.

Additionally, Gilead faces intense competition from established pharmaceutical and smaller biotech firms. Rapid technological advancements and evolving treatment paradigms characterize the industry. Competitors may develop new therapies or gain regulatory approvals threatening Gilead's market share. The company must continue to invest in research and development to maintain its competitive edge.

Clinical trial failures and delays are also inherent risks in the biopharmaceutical industry. Despite rigorous research and development processes, there is always a possibility that promising drug candidates may fail to meet efficacy or safety requirements during clinical trials. These setbacks can result in significant financial losses and delays in product launches, impacting Gilead's revenue streams.

Additionally, Gilead faces the challenge of addressing changing treatment landscapes and shifting patient preferences. Medical advancements, scientific discoveries, and evolving disease patterns can alter the demand for specific therapies. Gilead must anticipate and adapt to these changes to ensure its products remain relevant and effective.

Risk management is crucial for Gilead Sciences to mitigate potential challenges. The company employs rigorous clinical trial protocols, invests in diverse therapeutic areas, and pursues strategic partnerships to diversify its product portfolio. Gilead's strong financial position allows it to navigate uncertainties and invest in research and development initiatives. Furthermore, the company monitors regulatory developments and engages with policymakers to shape favorable healthcare policies.

GILD Stock Price History

GILD Stock News Headlines

Biotech Sector Nears Breakout: Will it Outperform in Q2?
The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Gilead Sciences (GILD) to Release Earnings on Thursday
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
11 Best Biotech ETFs To Buy
GILD May 2024 70.000 call
My April Dividend Stock Buys With Yields Up To 12%
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 3/28 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$5.67 billion
Pretax Margin


Sales & Book Value

Annual Sales
$27.12 billion
Cash Flow
$8.84 per share
Book Value
$18.26 per share


Outstanding Shares
Free Float
Market Cap
$83.33 billion

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Daniel P. O'Day (Age 60)
    Chairman & CEO
    Comp: $6.99M
  • Mr. Andrew D. DickinsonMr. Andrew D. Dickinson (Age 54)
    Chief Financial Officer
    Comp: $2.66M
  • Ms. Deborah H. Telman (Age 59)
    Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
    Comp: $2.56M
  • Ms. Johanna  MercierMs. Johanna Mercier (Age 54)
    Chief Commercial Officer
    Comp: $3.1M
  • Dr. Merdad V. Parsey M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $2.79M
  • Ms. Sandra Patterson (Age 57)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Ms. Jacquie Ross C.F.A.
    Vice President of Investor Relations
  • Ms. Jyoti K. Mehra (Age 48)
    Executive Vice President of Human Resources
  • Dr. Linda Slanec Higgins Ph.D. (Age 62)
    Senior Vice President of Research, Innovation & Portfolio
  • Dr. Rudolf Ertl (Age 78)
    Senior Vice President of Commercial Operations of Australia, Canada, Europe

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained


Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • Gilead Sciences has a diverse portfolio of products catering to various medical needs, including treatments for HIV/AIDS, viral hepatitis, oncology, and other serious infections.
  • The company recently introduced Veklury, an injection for intravenous use, for the treatment of COVID-19, which has shown promising results and could contribute significantly to the company's revenue.
  • With a market capitalization of $86.63 billion, Gilead Sciences is a well-established player in the biopharmaceutical industry, providing stability and potential growth opportunities for investors.
  • The stock price of Gilead Sciences has been relatively stable, with a current price of $69.58, making it an attractive option for value investors looking for steady returns.
  • Gilead Sciences has strategic collaborations with several prominent companies in the biopharmaceutical sector, enhancing its research capabilities and potential for future innovations.


Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • Gilead Sciences has faced challenges in maintaining consistent revenue growth, particularly due to patent expirations and increasing competition in the biopharmaceutical market.
  • The company's stock performance has shown some volatility, with fluctuations in the stock price that may deter risk-averse investors seeking more stable investment options.
  • Gilead Sciences' debt-to-equity ratio of 1.08 indicates a moderate level of debt, which could pose risks in times of economic uncertainty or rising interest rates.
  • Despite its collaborations, Gilead Sciences may face hurdles in translating research partnerships into successful commercial products, impacting its long-term growth prospects.
  • The biopharmaceutical industry is highly regulated and subject to rapid technological advancements, posing challenges for companies like Gilead Sciences to stay competitive and innovative.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

GILD Stock Analysis - Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings
or view top-rated stocks.

What is Gilead Sciences' stock price target for 2024?

15 brokerages have issued 1 year price objectives for Gilead Sciences' stock. Their GILD share price targets range from $71.00 to $105.00. On average, they expect the company's share price to reach $85.36 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price.
View analysts price targets for GILD
or view top-rated stocks among Wall Street analysts.

How have GILD shares performed in 2024?

Gilead Sciences' stock was trading at $81.01 at the start of the year. Since then, GILD stock has decreased by 17.4% and is now trading at $66.93.
View the best growth stocks for 2024 here

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 22,570,000 shares, an increase of 17.2% from the March 15th total of 19,250,000 shares. Based on an average daily volume of 7,440,000 shares, the days-to-cover ratio is currently 3.0 days.
View Gilead Sciences' Short Interest

When is Gilead Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our GILD earnings forecast

How can I listen to Gilead Sciences' earnings call?

Gilead Sciences will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Tuesday, February, 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts' consensus estimates of $1.76 by $0.04. The biopharmaceutical company earned $7.12 billion during the quarter, compared to analysts' expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a trailing twelve-month return on equity of 38.85%. The firm's revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.67 earnings per share.
Read the conference call transcript

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, February 1st. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share on Thursday, March 28th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.60%. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from the stock's previous quarterly dividend of $0.75.
Read our dividend analysis for GILD

Is Gilead Sciences a good dividend stock?

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $3.08 per share and currently has a dividend yield of 4.55%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 68.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GILD will have a dividend payout ratio of 42.08% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of 6.850-7.250 for the period, compared to the consensus earnings per share estimate of 7.210. The company issued revenue guidance of $27.1 billion-$27.5 billion, compared to the consensus revenue estimate of $27.7 billion.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.11%), Confluence Investment Management LLC (0.10%), Miller Howard Investments Inc. NY (0.06%), Meyer Handelman Co. (0.03%), CWM LLC (0.03%) and AMF Tjanstepension AB (0.03%). Insiders that own company stock include Andrew D Dickinson, Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Johanna Mercier, Merdad Parsey and Richard James Whitley.
View institutional ownership trends

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Gilead Sciences have any subsidiaries?
The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More
This page (NASDAQ:GILD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners